{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:39:28Z","timestamp":1792305568892,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.nmd.2025.105300","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T17:08:26Z","timestamp":1738775306000},"page":"105300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Bone mineral density changes in patients on drug therapy for spinal muscular atrophy"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4894-7669","authenticated-orcid":false,"given":"Abdelrahman","family":"Osman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halley","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Broomall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.nmd.2025.105300_bib0001","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.nmd.2017.01.019","article-title":"Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity","volume":"27","author":"Wasserman","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2025.105300_bib0002","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","author":"Farrar","year":"2013","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.nmd.2025.105300_bib0003","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00223-001-0048-8","article-title":"The \"muscle-bone unit\" in children and adolescents","volume":"70","author":"Schoenau","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.nmd.2025.105300_bib0004","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bone.2019.01.003","article-title":"Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review","volume":"121","author":"Nasomyont","year":"2019","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.nmd.2025.105300_bib0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2025.105300_bib0006","article-title":"Nusinersen for spinal muscular atrophy","volume":"11","author":"Ludolph","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.nmd.2025.105300_bib0007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","article-title":"Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever","volume":"9","author":"Mahajan","year":"2019","journal-title":"Int J Appl Basic Med Res"},{"issue":"6","key":"10.1016\/j.nmd.2025.105300_bib0008","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/acsmedchemlett.0c00659","article-title":"Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines","volume":"12","author":"Ratni","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.nmd.2025.105300_bib0009","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/apa.16974","article-title":"Low bone mineral density and reduced bone-specific alkaline phosphatase in 5q spinal muscular atrophy type 2 and type 3: a 2-year prospective study of bone health","volume":"112","author":"Kroksmark","year":"2023","journal-title":"Acta Paediatr"},{"issue":"2","key":"10.1016\/j.nmd.2025.105300_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jocd.2009.01.005","article-title":"Revised pediatric reference data for the lateral distal femur measured by hologic discovery\/Delphi dual-energy X-ray absorptiometry","volume":"12","author":"Zemel","year":"2009","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.nmd.2025.105300_bib0011","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.mph.0000162526.77400.78","article-title":"Cross-sectional study of bone mineral density in adult survivors of solid pediatric cancers","volume":"27","author":"Kelly","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.nmd.2025.105300_bib0012","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1210\/jc.2011-1111","article-title":"Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study","volume":"96","author":"Zemel","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.nmd.2025.105300_bib0013","doi-asserted-by":"crossref","first-page":"e3887","DOI":"10.1210\/clinem\/dgac323","article-title":"Reference ranges for bone mineral content and density by dual energy X-Ray absorptiometry for young children","volume":"107","author":"Kalkwarf","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nmd.2025.105300_bib0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jocd.2014.01.004","article-title":"Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions","volume":"17","author":"Bishop","year":"2014","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.nmd.2025.105300_bib0015","doi-asserted-by":"crossref","unstructured":"Iolascon G., Paoletta M., Liguori S., Curci C., Moretti A. Neuromuscular diseases and bone. Front Endocrinol (Lausanne). 2019 Nov 22;10:794. doi: 10.3389\/fendo.2019.00794. PMID: 31824418; PMCID: PMC6886381.","DOI":"10.3389\/fendo.2019.00794"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:59:53Z","timestamp":1741928393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":15,"alternative-id":["S0960896625000276"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105300","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone mineral density changes in patients on drug therapy for spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.105300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105300"}}